Bio & Pharma
MedPacto gets FDA OK for colorectal cancer drug clinical trial
It will carry out the Phase 2b/3 clinical trial to evaluate the efficacy of Vactosertib and Pembrolizumab combination therapy
By Jan 03, 2024 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a combination therapy using Vactosertib and pembrolizumab (product name: Keytruda)
This trial will focus on patients previously undergoing metastatic colorectal cancer treatment.
It is a phase 2b/3 trial designed to assess the efficacy of the combination therapy with Vactosertib and Pembrolizumab.
The primary endpoint for this trial will be overall survival (OS). The trial is planned as a multi-national effort, including South Korea and the US locations.
MedPacto will conduct this trial with the support of Pembrolizumab provided free of charge by Merck (MSD), under a clinical trial collaboration and supply agreement.
Write to Yoo-Rim Kim at youforest@hankyung.com
This trial will focus on patients previously undergoing metastatic colorectal cancer treatment.
It is a phase 2b/3 trial designed to assess the efficacy of the combination therapy with Vactosertib and Pembrolizumab.
The primary endpoint for this trial will be overall survival (OS). The trial is planned as a multi-national effort, including South Korea and the US locations.
MedPacto will conduct this trial with the support of Pembrolizumab provided free of charge by Merck (MSD), under a clinical trial collaboration and supply agreement.
Write to Yoo-Rim Kim at youforest@hankyung.com
More to Read
-
Bio & PharmaMedPacto's anti-cancer substance designated as US FDA fast-track item
Jan 18, 2023 (Gmt+09:00)
1 Min read -
BiotechKorea’s MedPacto, Merck plan phase 3 trials of colorectal cancer drug
Dec 15, 2021 (Gmt+09:00)
2 Min read
Comment 0
LOG IN